HLA-B Alleles with Shared Peptide Binding Specificities Define Global Risk of Cotrimoxazole-induced SCAR

Competing Interest Statement

E.J.P. receives royalties and consulting fees from UpToDate and UpToDate Lexidrug (where she is a Drug Allergy Section Editor and section author) and has received consulting fees from Janssen, Verve, Servier, Rapt and Esperion and Glenmark. E.J.P. and S.M. are co-directors of IIID Pty Ltd, which holds a patent for HLA-B*57:01 testing for abacavir hypersensitivity, and E.J.P., S.M. and A.C. hold a patent for detection of HLA-A*32:01 in connection with diagnosing drug reaction with eosinophilia and systemic symptoms to vancomycin. For these patents the authors do not receive any financial remuneration, and neither are related to the submitted work. A.M.D. receives compensation from the British Journal of Dermatology (reviewer and Editor), American Academy of Dermatology (guidelines writer), Canadian Dermatology Today (manuscript writer), National Eczema Association (consultant) and Canada's Drug Agency (consultant). All other authors declare no competing interests.

Funding Statement

This research was supported by National Institutes of Health (NIH) awards R01HG010863 (E.J.P.), NIH P50GM115305 (E.J.P.), NIH R01AI152183 (E.J.P. and J.P.), and NIH K23EY028230 (H.N.S. and E.J.P.), the NHMRC of Australia grant GNT11234999 (E.J.P.), and The Angela Anderson Fund and the SJS Research Fund (philanthropic support through VUMC) (E.J.P.). Authors also received funding from NIH U01AI154659 (E.J.P.) and NIH R21AI139021 (E.J.P.), NIH 2 D43 TW010559 (E.J.P., J.P., and R.L.), NIH K43 TW011178-01 (J.P.), NIH K08AI185260 (M.S.K.), NIH Core Grant EY001792 (H.N.S.), and an unrestricted departmental grant from Research to Prevent Blindness (H.N.S.), the AAAAI Foundation (M.S.K.), the Western Australian Future Health Research and Innovation Fund/ Western Australian Department of Health grant WANMA/EL2022/4 (A.G.), and the NHMRC of Australia grant GNT2028952 (A.G., E.J.P., and A.C.). A.M.D. has received research grants to his institution from the National Eczema Association, Eczema Society of Canada, Canadian Dermatology Foundation, Canadian Institutes for Health Research, NIH and Physicians Services Incorporated Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All samples and data were obtained with informed consent under institutional review board (IRB) approvals from VUMC (IRB 131836, 150754, 210027, 191350, 171900), MEEI (IRB 654182), Walter Sisulu University (HREC 056/2020), University of Cape Town (HREC R031/2018, 500/2018), Austin Health (HREC 50791/Austin-2019), and Murdoch University (HREC 2011/056, 2017/246, 2019/153). Samples and data were de-identified.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes